Houston regenerative medicine company to IPO, move toward more human trials

ready to list

FibroBiologics will IPO this week. Photo via Getty Images

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.”

O’Heeron was first exposed to the possibilities of fibroblasts as a means of regrowing discs in the spine. Since starting the company in 2008 as SpinalCyte, O’Heeron and FibroBiologics have organically written and filed more than 320 patents. Potential treatments go far beyond spinal surgery to include wound care, cancer, and multiple sclerosis.

According to O’Heeron, the goal in going public is to raise capital for human trials.

“We’ve had really fantastic results with animals and now we’re ready for humans,” he explained in September. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

FibroBiologics is growing with impressive speed. O’Heeron told us that he is hiring as quickly as he is able to find qualified scientists with the expertise to do the one-of-a-kind work required. The company opened a new lab last fall at the UH Technology Bridge, Newlin-Linscomb Lab for Cell Therapies. With its new status as a publicly traded company, FibroBiologics is primed to break even more ground.

FibroBiologics is opening a unique new lab at the University of Houston's Technology Bridge. Photo by Natalie Harms/InnovationMap

Houston regenerative medicine company opens new lab at UH

cell therapy innovation

Pete O’Heeron wants you to know that “Bohemian Rhapsody” was originally released as a B-side. What does this nugget about Queen have to do with regenerative medicine? For O’Heeron and his company, FibroBiologics, it means everything.

That’s because most scientists consider stem cells the A-side when it comes to the race to curing disease. But FibroBiologics has set its sights on fibroblasts. The most common cell in the body, fibroblasts are the main cell type in connective tissue.

“Everyone was betting on stem cells, and we started betting on fibroblasts,” says O’Heeron, who started the company in 2008 as SpinalCyte. “I think what we're going to see is that fibroblasts are going to end up winning, there are more robust, more that are lower cost cell, they have higher therapeutic values, higher immune modulation. They're just a better overall cell than the than the stem cells.”

Since a neurosurgeon and a dermatologist first introduced O’Heeron to the idea of using fibroblasts to regrow discs in the spine, the company has expanded its reach to include promising treatments for multiple sclerosis and cancer and in wound care. Imagine a world where doctors lay fibroblasts directly onto surgical incisions after surgery, cutting the time for healing in half.

FibroBiologics has organically written and filed more than 320 patents.

“It's quite a unique situation. I don’t think that in other areas of science that you have such a wide open area to go out and patent. It's just it was a brand new area nobody had been working on,” O’Heeron explains.

And soon, investors will be able to own a stake in the impressive work being forged in Houston. FibroBiologics, previously FibroGenesis, was formed in order to go public in a direct NASDAQ listing. The goal is to access the capital necessary to go to human trials. Earlier this year, the company also launched a crowdfunding campaign.

“We’ve had really fantastic results with animals and now we’re ready for humans,” says O’Heeron. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

With that in mind, the company just signed a deal with University of Houston’s Innovation Center. On Thursday, September 7, FibroBiologics will dedicate the Newlin-Linscomb Lab for Cell Therapies in the UH Technology Bridge. The new lab is named for former player and color commentator for the Houston Rockets, Mike Newlin and his wife, Cindy, as well as Pam and Dan Linscomb, a founding partner of Kuhl-Linscomb, one of the largest wealth management companies in Houston.

Other big local names newly attached to the company are astronaut Kate Rubins and Elizabeth Shpall, the director of the cell therapy laboratory at MD Anderson Cancer Center. Both have joined FibroBiologics as members of its scientific advisory board.

To fill the lab, O’Heeron says that he is adding to his team as quickly as he is able. The barrier is the fact that there are few, if any people in the world with the exact qualifications he’s seeking.

“Anytime you're breaking new scientific ground, you can't really just go out and recruit someone with that background because it really doesn't exist,” he says. But he is willing to teach and challenge scientists who are the right fit, and is hoping to expand the team in the new lab.

But like Queen did in 1975, FibroBiologics is pioneering a category of its own. And that’s something worth betting on.

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

Houston biopharma company launches equity crowdfunding campaign

money moves

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas institute grants $12M to bring leading cancer researchers to Houston

cha-ching

Rice University has recruited a prominent Swedish cancer researcher thanks to a $6 million grant from the Cancer Prevention and Research Institute of Texas.

It’s among $68 million in research grants recently awarded by the state agency, and six recruitment grants totaling $16 million to bring leading cancer researchers to Texas.

A news release from the Cancer Prevention and Research Institute of Texas (CPRIT) describes Pernilla Wittung-Stafshede of the Chalmers University of Technology in Gothenburg, Sweden, as “an accomplished and highly gifted biophysical scientist tackling complicated biological questions regarding the role of metals and metal dysregulation in various diseases. She pioneered a new research field around the role of metal ions in the folding and function of metalloproteins.”

Metalloproteins account for nearly half of all proteins in biology, according to the National Institutes of Health. They “catalyze some of the most difficult and yet important functions in [nature], such as photosynthesis and water oxidation,” the federal agency says.

Wittung-Stafshede, a professor of chemical biology and life sciences at Chalmers, is a former professor at Rice.

Aside from the money for Wittung-Stafshede, Houston recruitment grants also went to:

  • University of Texas M.D. Anderson Cancer Center: $2 million to recruit Rosalie Griffin of the Mayo Clinic
  • Baylor College of Medicine: $2 million to recruit Dr. Nipun Verma of the Yale University School of Medicine
  • Baylor College of Medicine: $2 million to recruit Xin “Daniel” Gao of Harvard University and the Massachusetts Institute of Technology

In Houston, cancer research grants were given to:

  • Baylor College of Medicine: $7.8 million
  • M.D. Anderson Cancer Center: $20.7 million
  • Rice University: $ 1 million
  • University of Houston: $1.2 million
  • University of Texas Health Science Center at Houston: $4.5 million

“The awards … represent the depth and diversity of CPRIT funding for cancer research in Texas,” says Kristen Doyle, CEO of CPRIT. “These grants develop new approaches to preventing, diagnosing, treating, and surviving cancer for all Texans.”

See the full list of awards here.

2 Houston startups win big at SXSW 2025 pitch competition

winner, winner

Houston had a strong showing at this week's SXSW Pitch showcase in Austin, with two local startups claiming top prizes in their respective categories.

Little Place Labs, a Houston space data startup, won the Security, GovTech & Space competition. Clean-tech company Helix Earth, which spun out of Rice University and was incubated at Greentown Labs, won in the Smart Cities, Transportation & Sustainability contest.

As one of SWSX's marquee events, held March 8-10, the pitch competition featured 45 finalists, selected from 589 applicants, in nine categories.

"We faced impressive competition from a well-chosen set of finalists, and we're honored to be chosen as the winners. One of the judges even commented, ‘Who knew you could make air conditioning sexy,’” Brad Husick, Helix's co-founder and chief business officer, said in a release.

Helix Earth was launched in 2022 and is known for its space capsule air filtration system that was co-developed for NASA. The commercial air conditioner add-on technology, now in a pilot phase, has been used to retrofit HVAC systems for commercial buildings and can save up to 50 percent of the net energy, cutting down on emissions and operating costs, according to the company. Its co-founder and CEO Rawand Rasheed was named to the Forbes 30 Under 30 Energy and Green Tech list for 2025.

“This win validates our mission to drive sustainable innovation in commercial air conditioning and beyond. We are excited about the future of Helix Earth and the impact we will have in reducing energy consumption and emissions," Rasheed said in a statement.

Little Place Labs echoed that sentiment with a post on LinkedIn celebrating the win.

"This all started with a simple mission: To deliver real-time space insights to help first responders, mission planners, and decision-makers act before problems arise,” the post read. "Today, that mission feels even stronger."

The company uses advanced AI and machine learning to deliver near-real-time space analytics for both ground and space-based applications. Its software aims to help first responders, mission planners and decision-makers detect anomalies and make informed decisions quickly. It was co-founded in 2020 at Oxford by Houstonian and CEO Bosco Lai and Gaurav Bajaj and participated in the 2023 AWS Space Accelerator.

Two other Houston companies were selected as finalists:

  • Trez, a Latino-focused fintech company that uses AI and voice-command payroll through WhatsApp to provide culturally relevant payroll and streamline financial operations for Latino business owners.
  • Tempesst Droneworx, a veteran-owned software company that's Harbinger software providing real-time contextual intelligence for early warning detection, reducing time to decision and speeding time to action.

Jesse Martinez, founder of invincible, and Anu Puvvada of KPMG were two judges representing Houston.

According to SXSW, 647 companies have participated in SXSW Pitch over the years, with over 93 percent receiving funding and acquisitions totaling nearly $23.2 billion. See the full list of 2025 winners here.

A legacy of industrial technology excellence: UTSI International turns 40

Cheers to 40 Years

As UTSI International celebrates its 40th anniversary, president and CEO Shaun Six reflects on the company's history, achievements, and exciting future.

---

In March 1985, Dan Nagala and a few friends took a risk, leaving their full-time jobs to pursue their passion and start their own company.

They founded UTSI Internationalamidst groundbreaking advancements in Industrial Control Systems and SCADA technology, revolutionizing remote operations for critical infrastructure. From the start, UTSI has been at the forefront of OT innovation and integration — a legacy we proudly carry forward today.

The legacy of Dan Nagala

Dan Nagala’s 50-plus-year career is too vast to cover every accomplishment, but if you’ve ever heard the phrase “Houston, we have a problem” in a movie, those screens in the control room and the logic causing the “blinky lights” to alert the operators, you’ve seen some of his work. Dan and his team ultimately paved the way for field communications to detect and communicate leaks on pipelines and give operators in remote locations situational awareness, expanding their ability to safely monitor and control their operations.

This capability was requested early on in the first pipeline control rooms, leading to UTSI’s first check-in 1985 (which I proudly have framed on my bookshelf). The protocols to communicate and do advanced calculations — which many would be tempted to call AI today — for the purpose of monitoring and control, was created from this group of enthusiasts who open sourced it and allowed it to proliferate, leading to over 80 percent of all critical infrastructure in the world now utilizing a variant thereof.

Given the novelty of the technology and the experience of UTSI, having implemented control systems and automation for pipelines in over 22 countries, Dan was asked to collaborate with industry experts, creating the first API leak detection and control room management standards for the American Petroleum Institute. These would later become regulation under PHMSA, DoT, and TSA, placing UTSI as the go-to experts in compliance in addition to their traditional expertise.

UTSI has delivered for the world’s largest infrastructure owners in multiple critical infrastructure sectors, like mining, water/wastewater, oil and gas, green energy, transportation authorities, etc. We have also done AI and cybersecurity, in addition to SCADA and ICS work for the DoD and DoE.

Strength in partners

I joined UTSI in 2022 as vice president, working under Dan, with the goal of gradually stepping into leadership. In 2023, I became CEO, president, and majority shareholder. While no one can truly fill Dan’s shoes alone, we’ve focused on strengthening our team, partnerships, and capabilities to continue UTSI’s legacy of excellence.

One of our first strategic partnerships was with Tory Tech, a leading API-compliant Control Room Management tool. UTSI has worked as integrators with Tory Tech for years and Dan worked as a CRM compliance advisor for them in the U.S. while they were setting up their headquarters in Houston. In 2024 we made it an official partnership, becoming a preferred integrator and focusing our team on training and development in the MaCRoM (Master Control Room Management) tool.

We've also made significant investments in our OT cybersecurity capabilities, expanding our team and partnering with industry leaders like Dennis Parker, Derrik Oates, Nozomi Networks, Fortinet, and Schneider Electric. These strategic moves ensure we deliver top-tier expertise, products, and solutions to better serve our customers.

Our partnership with ThreatGEN and the utilization of their AI-driven “AutoTableTop” tool not only utilizes our experience with TSA guidelines, but adds an element of reality that the traditional methods are lacking, making these engagements more interactive and beneficial for operators who are required to participate annually.

In 2024, UTSI also invested heavily in AI and Data Science by acquiring Houston-based AI company Pandata Tech and leveraging their Data-Quality-Methodology (DQM), Leak Geek, and time-series data science expertise to solve industry specific problems.

Moving up – in and around Houston

Building on our recent successes, we strategically relocated our office to the Netrality building (1301 Fannin St.), bringing us closer to clients and partners, while getting access to a Tier 3 Data Center with an uninterrupted 40-year power record.

Netrality is a SOC2-compliant facility with seven points of detection from the street to our server, including biometric screening. Our very own Roberto deLeon has architected our upgraded servers using the Purdue model as a basis of design while leveraging our relationship with Fortinet to standardize our hardware and software to the highest standards. We practice what we preach — every architecture, framework, and hardware recommendation we make is not just advised but actively implemented within our own operations.

Our investment in this space includes increasing our “SCADA R&D Lab” to play with toys from vendors, testing them out in our environment before we recommend and advise them to our clients and partners. Currently we’re working on LLMs for OT, building our own “DANN2.0” for use in-house. DANN is an homage to Dan Nagala (and, for the nerds, stands for Dan Artificial Neural Network), which we started in 2022 when I realized that knowledge capture is an industry wide epidemic and we need to be ready to integrate for our clients in a safe and local way at scale, in the OT environment.

Additionally, having come from a startup before joining UTSI, I wanted to get us closer to the heart of innovation, so we’ve added additional office space at The Cannon downtown. While there are many tech hubs around Houston, and we are proud to work with and partner with companies from Greentown Labs and the Ion, to name a few, we’ve found that The Cannon community is incredibly active and innovative, with experience in industrial use-cases.

Houston is set to become the Energy Transition capital, leading in hydrogen, carbon capture, and repurposing. With a 5:1 ratio of engineers leaving the industry and an average age over 60, we must innovate. The solution lies in combining a secure, cloud-free "ChatGPT for OT" with digital twins. Bringing the field to engineers is essential. We've partnered with a satellite constellation for asset imaging and U.K.-based Mods Solutions to leverage their CFIHOS-driven platform for intelligent digital twins — more on that partnership soon!

And we will need to leverage enhanced automation tools and actively monitor control networks to ensure security and respond quickly to issues, which is why we’ve partnered with Nozomi Networks.

Shaping the future

Although Dan has semi-retired to his cabin in Montana, he continues to do “the fun stuff” that brings him joy, such as conducting research for PRCI and assisting long-time clients. He also has been a mentor and advisor to me since I started at UTSI three years ago. I’m grateful for him and the group of industry experts he gathered around him to make UTSI such a well-known systems integrator and OT advisor for the world’s largest asset owners.

Our group of experts are active in the industry and will be speaking at events throughout the year, with a presence at Entellec, Level Zero, and participating at this year's API Cybernetics and PSIGs biannual conferences. We proudly serve on the BCarbon advisory board and GHPs Energy Committee.

Lastly, we have one request: We see a critical need for H2 and supercritical CO2 studies to develop simulation models, response plans, and leak detection best practices. These gases differ from those covered in existing standards. If you know anyone interested in funding or contributing, we’re collaborating with industry partners to secure support.

View All Listings